State Board of Administration of Florida Retirement System Buys 2,739 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

State Board of Administration of Florida Retirement System lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 5.1% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,840 shares of the medical research company’s stock after acquiring an additional 2,739 shares during the period. State Board of Administration of Florida Retirement System owned approximately 0.11% of Charles River Laboratories International worth $15,401,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of CRL. Koshinski Asset Management Inc. bought a new position in shares of Charles River Laboratories International in the first quarter worth approximately $279,000. J.P. Marvel Investment Advisors LLC lifted its position in Charles River Laboratories International by 1.8% in the 1st quarter. J.P. Marvel Investment Advisors LLC now owns 39,486 shares of the medical research company’s stock worth $10,699,000 after buying an additional 709 shares during the last quarter. Bleakley Financial Group LLC purchased a new stake in Charles River Laboratories International in the first quarter worth approximately $224,000. Russell Investments Group Ltd. grew its position in Charles River Laboratories International by 31.9% during the first quarter. Russell Investments Group Ltd. now owns 37,074 shares of the medical research company’s stock valued at $10,045,000 after acquiring an additional 8,959 shares during the last quarter. Finally, Qsemble Capital Management LP bought a new stake in shares of Charles River Laboratories International in the 1st quarter worth approximately $995,000. Hedge funds and other institutional investors own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 1.3 %

NYSE CRL traded down $2.77 during mid-day trading on Friday, reaching $215.81. The stock had a trading volume of 110,207 shares, compared to its average volume of 529,616. The stock has a market cap of $11.12 billion, a PE ratio of 25.43, a price-to-earnings-growth ratio of 2.11 and a beta of 1.38. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The company has a debt-to-equity ratio of 0.73, a current ratio of 1.75 and a quick ratio of 1.37. The company has a fifty day moving average price of $213.43 and a 200 day moving average price of $230.27.

Charles River Laboratories International (NYSE:CRL) last issued its quarterly earnings data on Thursday, May 9th. The medical research company reported $2.27 earnings per share for the quarter, beating analysts’ consensus estimates of $2.05 by $0.22. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $997.24 million. Charles River Laboratories International had a net margin of 10.81% and a return on equity of 15.16%. On average, research analysts expect that Charles River Laboratories International, Inc. will post 11 earnings per share for the current year.

Analyst Ratings Changes

CRL has been the topic of a number of recent research reports. Mizuho assumed coverage on Charles River Laboratories International in a research note on Friday, June 7th. They set a “neutral” rating and a $235.00 price objective on the stock. TD Cowen dropped their target price on shares of Charles River Laboratories International from $260.00 to $228.00 and set a “hold” rating for the company in a report on Monday, May 13th. The Goldman Sachs Group began coverage on Charles River Laboratories International in a report on Thursday, June 6th. They set a “buy” rating and a $290.00 price target on the stock. Robert W. Baird dropped their price target on Charles River Laboratories International from $271.00 to $239.00 and set an “outperform” rating for the company in a research note on Wednesday, July 10th. Finally, Argus restated a “hold” rating on shares of Charles River Laboratories International in a report on Friday, June 28th. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $252.29.

Insider Activity at Charles River Laboratories International

In other news, EVP Joseph W. Laplume sold 1,304 shares of the company’s stock in a transaction dated Friday, May 10th. The shares were sold at an average price of $226.97, for a total transaction of $295,968.88. Following the completion of the sale, the executive vice president now owns 23,276 shares of the company’s stock, valued at approximately $5,282,953.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).